Even the best cell lines have quirks. Here are three frequent challenges and their solutions.
Furthermore, industry analysts predict that by 2027, the adoption of next-gen lines like Vivacell Hamarner will surpass traditional CHO cells in commercial biomanufacturing, primarily due to the cost savings from higher volumetric productivity.
Even the best cell lines have quirks. Here are three frequent challenges and their solutions.
Furthermore, industry analysts predict that by 2027, the adoption of next-gen lines like Vivacell Hamarner will surpass traditional CHO cells in commercial biomanufacturing, primarily due to the cost savings from higher volumetric productivity. vivacell hamarner
